.jpg "Analysts Offer Insights on Healthcare Companies: Agile Therapeutics (NASDAQ: AGRX), Rocket Pharmaceuticals Inc (NASDAQ: RCKT) and Nektar Therapeutics (NASDAQ: NKTR)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agile Therapeutics (NASDAQ: AGRX), Rocket Pharmaceuticals Inc (NASDAQ: RCKT) and Nektar Therapeutics (NASDAQ: NKTR) with bullish sentiments.
Agile Therapeutics (NASDAQ: AGRX)
H.C. Wainwright analyst Oren Livnat assigned a Buy rating to Agile Therapeutics (NASDAQ: AGRX) today and set a price target of $4. The company’s shares closed on Friday at $0.69, close to its 52-week low of $0.58.
Livnat noted:
“We have all along thought the primary approval sticking point was ultimately about Twirla’s relative efficacy, but now it’s just the sticking itself. The prior Complete Response Letter called out potential concerns on Twirla adhesion and the possible impact on efficacy, so Agile went into its Type A FDA meeting with a deluge of adhesion data and analyses showing no correlation of peeling or detachment with pregnancies. However, per the meeting minutes announced Friday, the FDA division is now concerned with the patch detachment rate, in and of itself, and is unmoved by Agile’s plan to deal with detached patches in practice.”
According to TipRanks.com, Livnat has 0 stars on 0-5 star ranking scale with an average return of -10.5% and a 39.7% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Currently, the analyst consensus on Agile Therapeutics is Strong Buy and the average price target is $9, representing a 1204.3% upside.
In a report issued on May 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $4 price target.
See today’s analyst top recommended stocks >>
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)
In a report released yesterday, Phil Nadeau from Cowen & Co. assigned a Buy rating to Rocket Pharmaceuticals Inc (NASDAQ: RCKT). The company’s shares closed on Friday at $19.90, close to its 52-week high of $22.40.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 13.9% and a 56.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.
Rocket Pharmaceuticals Inc has an analyst consensus of Moderate Buy.
Nektar Therapeutics (NASDAQ: NKTR)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright assigned a Buy rating to Nektar Therapeutics (NASDAQ: NKTR), with a price target of $125. The company’s shares closed on Friday at $85.30.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.7% and a 51.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $110.14, representing a 29.1% upside.
In a report issued on May 11, Mizuho Securities also maintained a Buy rating on the stock with a $103 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
